Is BPH the same as prostate cancer?

No. BPH is a non-cancerous enlargement of the prostate gland. It does not cause prostate cancer and does not increase cancer risk. However, both conditions can coexist, so evaluation by a doctor is important to rule out other causes of urinary symptoms — particularly if PSA levels are elevated.

Can BPH be treated without surgery?

Yes, most men with BPH are managed without surgery. Lifestyle changes are first-line for mild symptoms. Medications — alpha-blockers and 5-alpha reductase inhibitors — work well for moderate symptoms. Minimally invasive procedures offer alternatives to surgery for those who do not respond to medication.

Does BPH go away on its own?

BPH does not typically reverse without treatment. Symptoms may fluctuate but usually progress slowly over time. Early lifestyle changes and medical treatment can slow progression and substantially improve quality of life.

What is nocturia and is it always caused by BPH?

Nocturia — waking at night to urinate — is one of the most disruptive BPH symptoms. However, it can also be caused by sleep disorders, heart conditions, excessive fluid intake, diabetes, or bladder overactivity. A full assessment helps identify the cause, which guides the most effective treatment.

When is surgery needed for BPH?

Surgery is considered when medications fail to control symptoms, when there are complications such as recurrent urinary tract infections, bladder stones, kidney damage, or complete urinary retention, or when the man prefers a definitive solution. TURP is the most established surgical option, with good long-term outcomes.

How is BPH different from prostatitis?

BPH is a gradual, age-related non-cancerous enlargement of the prostate. Prostatitis is inflammation of the prostate — which can be bacterial or non-bacterial — and often causes pelvic pain and more acute symptoms. Both can affect urination but have different causes and treatments.

Benign Prostatic Hyperplasia (BPH): Symptoms, Diagnosis, and Treatment

Intro

Benign prostatic hyperplasia (BPH) is a non-cancerous enlargement of the prostate gland that is extremely common with advancing age. By age 60, more than half of men have some degree of BPH; by age 85, the figure approaches 90%. The enlarged prostate presses on the urethra, causing a range of lower urinary tract symptoms (LUTS) that can significantly affect quality of life.

BPH is not prostate cancer, does not cause cancer, and is treatable. The right management approach depends on symptom severity, individual health, and personal preference.

Key Points

BPH affects the majority of men over 60 and is the most common cause of lower urinary tract symptoms in men
Symptoms include weak urine stream, frequency, urgency, nocturia, incomplete bladder emptying, and hesitancy
Diagnosis is clinical — history, symptom score, urinalysis, and PSA testing to exclude prostate cancer
First-line treatment for mild symptoms is lifestyle modification
Medications (alpha-blockers, 5-alpha reductase inhibitors) are effective for moderate to severe symptoms
Surgery — including TURP — is reserved for significant symptoms or complications
BPH and prostate cancer can coexist; evaluation should exclude cancer where indicated

Background

The prostate gland surrounds the urethra at the base of the bladder. In BPH, overgrowth of prostate tissue — driven by hormonal changes as testosterone declines and dihydrotestosterone (DHT) remains influential — causes the gland to press on the urethra. This creates the characteristic “obstructive” symptoms of BPH.

The severity of symptoms does not always correlate with prostate size. Some men with significantly enlarged prostates have mild symptoms; others with modestly enlarged prostates experience substantial bother.

Symptoms

BPH produces two overlapping categories of lower urinary tract symptoms:

Obstructive (voiding) symptoms

Weak or slow urine stream — reduced force due to urethral narrowing
Hesitancy — difficulty initiating urination
Straining — having to push to start or maintain flow
Incomplete emptying — sensation that the bladder has not fully emptied
Dribbling after urination ends

Storage (irritative) symptoms

Frequency — needing to urinate more often than usual
Urgency — sudden, strong urge to urinate
Nocturia — waking one or more times per night to urinate

Symptom assessment

Doctors commonly use the International Prostate Symptom Score (IPSS) — a validated questionnaire scoring severity from 0 to 35. Scores guide treatment:

0–7: Mild — watchful waiting appropriate
8–19: Moderate — medication often recommended
20–35: Severe — medication or procedural intervention usually indicated

Red Flags Requiring Prompt Evaluation

Seek medical assessment promptly if you notice:

Complete inability to urinate (acute urinary retention) — a medical emergency
Blood in the urine (haematuria)
Recurrent urinary tract infections
Kidney function concerns on blood tests
Significant unexplained weight loss or bone pain (possible malignancy)
Rapidly worsening symptoms

Diagnosis

Clinical history

A doctor will review symptom duration, severity, fluid intake patterns, medications (diuretics, antihistamines, and decongestants can worsen symptoms), and other health conditions.

Physical examination

A digital rectal examination (DRE) estimates prostate size and assesses for nodules or firmness that might suggest cancer.

PSA (Prostate-Specific Antigen) testing

PSA is produced by the prostate and can be elevated in BPH, prostatitis, or prostate cancer. A mildly elevated PSA in the setting of BPH is common, but significant elevation warrants further investigation. PSA testing involves a shared decision with the patient, weighing benefits and potential harms of further workup.

Urinalysis

To exclude infection, blood, or glucose abnormalities.

Bladder diary and flow rate

Frequency-volume charts and uroflowmetry (measuring urine flow speed) can quantify symptoms and response to treatment.

Further tests (if indicated)

Post-void residual urine measurement (ultrasound)
Prostate size measurement (transrectal or abdominal ultrasound)
Referral to urology for urodynamic studies when diagnosis is uncertain

Differentiating BPH from Prostate Cancer

Both BPH and prostate cancer can cause similar urinary symptoms and elevated PSA. Key distinctions:

Feature	BPH	Prostate Cancer
Age of onset	Typically 50s–60s+	Typically 60s+
PSA	Can be elevated	Often elevated
DRE findings	Smooth enlargement	Firm, irregular nodule possible
Symptoms	Obstructive / storage	Can be similar or asymptomatic
Urgency/nature	Benign; progressive	Risk of spread if untreated

If prostate cancer is suspected — based on PSA level, rate of rise, DRE findings, or clinical risk — further investigation with MRI and possible biopsy is appropriate.

Treatment

1. Watchful waiting and lifestyle changes

For mild symptoms (IPSS ≤ 7) or if symptoms are not significantly bothersome:

Fluid management: reduce overall intake, limit caffeine and alcohol which increase urinary urgency
Timing: avoid large fluid intake in the 2 hours before bed to reduce nocturia
Double voiding: urinating, waiting a few minutes, then urinating again to improve bladder emptying
Pelvic floor awareness: relevant in some cases, discuss with your doctor
Review medications: some blood pressure medications, antihistamines, and decongestants worsen symptoms

2. Medications

Alpha-blockers (first-line for moderate to severe symptoms)

Alpha-blockers relax smooth muscle in the prostate and bladder neck, improving urine flow. They work quickly — often within days.

Common agents: tamsulosin, alfuzosin, silodosin, doxazosin

Side effects: dizziness, light-headedness (postural hypotension), retrograde ejaculation (with tamsulosin and silodosin).

5-alpha reductase inhibitors (5-ARIs)

These reduce prostate size by blocking conversion of testosterone to DHT. They work more slowly (3–6 months) but can reduce prostate volume by 20–30%.

Common agents: finasteride, dutasteride

Side effects: reduced libido, erectile dysfunction, decreased ejaculate volume; rarely, gynaecomastia.

Combination therapy (alpha-blocker + 5-ARI) provides greater symptom relief and slows disease progression in men with larger prostates.

Phosphodiesterase-5 (PDE5) inhibitors

Tadalafil (used for erectile dysfunction) is also approved for BPH-related LUTS. Useful when both BPH and erectile dysfunction are present.

3. Minimally invasive procedures

When medications are insufficient or not tolerated, minimally invasive options include:

Prostatic urethral lift (UroLift): implants hold prostate lobes apart — no tissue removal, faster recovery, low risk to sexual function
Rezūm (steam therapy): water vapour destroys excess prostate tissue; day procedure with gradual improvement
Transurethral microwave therapy (TUMT): microwave energy reduces prostate size
Aquablation: robotic water jet ablation, useful for larger or irregular glands

4. Surgery

Considered for significant symptoms, large prostate size, or complications:

TURP (Transurethral Resection of the Prostate): the established standard. Resects excess prostate tissue via a scope inserted into the urethra. Excellent long-term results. Requires anaesthesia and hospital admission. Side effects include retrograde ejaculation in most cases.
Holmium Laser Enucleation of the Prostate (HoLEP): increasingly used for large prostates; comparable outcomes to TURP with less bleeding risk.
Open/robotic prostatectomy: reserved for very large prostates or complex cases.

Nocturia and Sleep

Nocturia — waking to urinate at night — can have multiple contributing causes beyond BPH. Before attributing nocturia solely to BPH, consider discussing:

Sleep disorders including sleep apnoea, which alters bladder function overnight
Nocturnal polyuria — overproduction of urine at night, sometimes related to heart or kidney conditions
Evening fluid and caffeine habits

Treating nocturia often requires a multi-pronged approach. See Sleep and Health for broader context.

Long-term Outlook

Most men with BPH have a good prognosis. The condition progresses slowly, and treatment — from lifestyle changes to medication to surgery — is effective at managing symptoms. Complications (acute retention, bladder stones, kidney damage) are uncommon when BPH is identified and managed early.

Regular monitoring is appropriate to detect symptom progression or rising PSA.